Marie Gårdmark: Finally, it’s time for a revision of the EU pharma legislation

A challenge for the EU Commission is to deliver a new framework that will also take care of another “pillar” of the pharmaceutical strategy, namely, to ensure t...

Trump i nytt försök att pressa läkemedelspriser

USA:s president Donald Trump meddelade på söndagen att han tänker underteckna en presidentorder för att sänka priserna på receptbelagda läkemedel till samma niv...

ZEISS är redo för Elmia Verktygsmaskiner

Du kan få en demonstration av mätmaskinen ZEISS CONTURA.

Claims of life science companies fleeing abroad is a myth according to survey

The claim that life science companies are moving abroad is exaggerated. In fact, only a tiny percentage is leaving the country, according to a survey.

The investor: “The major common diseases are hot again”

She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...

New drug alert in the US: Rise in overdoses linked to the use of drugs for animals

A combination of the synthetic drugs fentanyl and xylazine, an animal tranquilizer, has been labelled a “growing threat” by the White House due to its role in t...

Come see us at the upcoming events!

We have some upcoming events where you can see our latest products live!

Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

Hon är MSD:s nya svenska vd

Birgitta Wikman Erlandson har utsetts till vd för MSD Sverige där hon de senaste året varit affärsområdeschef för vaccinavdelningen.

Anna Törner: You won’t find this many Concorde projects anywhere else

"Suddenly Concorde projects seem reasonable in life science because it´s about life and death", writes Anna Törner in a column.

FDA:s rådgivande vaccinmöte inställt – utan förklaring

Ett årligt möte mellan FDA och deras rådgivande vaccinkommitté ställs in.

Are you ready for EMC 2024?

Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.

NorthX Biologics Matfors AB

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

ALS – When the body has given up, but the brain persists

with the outside world can continue. “It’s their window to the world,” says ALS researcher Caroline Ingre.

Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

CAR-T-terapin Carvykti rekommenderas i Sverige – behandling förbereds

Karolinska universitetssjukhuset har för första gången i Sverige inlett förberedelser för att behandla en patient med blodcancerformen multipelt myelom med CAR-...

A small thing that can solve your problems

If you are in need of a compact valve. Look no further! We have the VOVK

“An entire industry is about to be wiped out”

According to Jennie Ekbeck, CEO of Umeå Biotech Incubators, Sweden risks not having any small diagnostic companies left in five years.

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

Tio life science-projekt får miljonanslag – ny utlysning öppnar

En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.

Webinar: Medtech quality and regulatory compliance

This webinar is for you who are developing or planning to develop a medical device, combination, or borderline product. In one hour, we will discuss what you ne...

Major advances in IVF labs in the last few decades

Since the introduction of in vitro fertilisation several decades ago, many developments have been made in the field, and the main part of that development has t...